Designer Circular RNA as Protein Sponge for Cancer Therapy
The new circular RNA enables specific binding and inhibition of heterogeneous nuclear ribonucleoprotein L in cells and thus opens new therapeutic approaches for the treatment of pancreatic and other cancer types, where hnRNP L is deregulated.
The new circular RNA is very stable, it can easily be transfected into cells. It is used to sponge and thereby inhibit selectively hnRNP L.
Bilder & Videos
A new artificial circular RNA with an unusual ribonucleotide sequence was designed to bind and inhibit intracellular heterogeneous nuclear ribonucleoprotein L (hnRNP L). HnRNP L plays an essential role in the development of pancreatic and other cancer types.
- Circular RNA is much more stable than the corresponding linear RNA.
- Circular RNA can be designed to sponge RNA-binding proteins, thereby inhibiting the metabolic function of such proteins.
- Circular RNA can easily be introduced into cells and has no adverse side effects.
- A circular RNA was designed to bind hnRNP L with high specificity and affinity, inactivating this protein and thus opening up new therapy options for pancreatic and other cancer types, where hnRNP L is deregulated.
The new circular RNA is useful in pancreatic and oral squamous cell cancer therapy, when hnRNP L is overexpressed, based on binding and inhibiting intracellular heterogeneous nuclear ribonucleoprotein L (hnRNP L).
On behalf of its shareholder Justus-Liebig-Universität Giessen TransMIT GmbH is looking for cooperation partners or licensees for further development in Germany, Europe, US, and Asia.
TransMIT Gesellschaft für Technologietransfer mbH
Kerkrader Str. 3
StichworteCircular RNA, pancreatic cancer therapy, hnRNP L, heterogeneous nuclear ribonucleoprotein L, protein sponging, RNA-binding proteins, molecular medicine, oral squamous cell carcinoma therapy